Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome
Brain, Behavior, & Immunity - Health · 2025-10 · 48 · 101048
DOI: 10.1016/j.bbih.2025.101048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, & Immunity - Health, 2025-10. Verfasst von Leonard B Weinstock und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Gastrointestinal Alliance, 11525 Olde Cabin Road, St. Louis, MO, 63141, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neuropsychiatric disorders have been observed in mast cell activation syndrome (MCAS). MCAS is a common, yet rarely diagnosed, inflammatory, and immunologic disease characterized by mast cell dysregulation.
Methods
Questionnaires from 553 MCAS and 558 control subjects determined the prevalence and odds ratio of neurologic disorders (fatigue, cognitive dysfunction, fainting/near fainting, migraine-like headaches, muscle pain/tenderness/weakness, pain/numbness/tingling in extremities, restless legs syndrome, seizure-like activity, insomnia, sleep attacks, tinnitus, acoustic startle, Tourette's syndrome, resting tremor, and light/sun/pain/odors/scents/noise hypersensitivity) and psychiatric disorders (anxiety, agoraphobia, panic attacks, depression, bipolar depression, mania/hypomania, psychosis/schizophrenia, hallucinations, obsessive compulsive disorder, attention-deficit/hyperactivity disorder, anger management problems, post-traumatic stress disorder, suicidal thoughts, and eating disorders).
Results
Among 19 neurologic disorders, female MCAS patients reported higher rates in all but 1 disorder and male MCAS patients reported higher rates in all but 2 disorders. Among 14 psychiatric disorders, female MCAS patients reported higher rates in all and male MCAS patients reported higher rates in 8 disorders. Many of the disorders with increased prevalences were statistically greater compared to corresponding controls.In self-reported ratings for effects on health status (0 = no benefit, 10 = maximum benefit), mean (SD) response was 6.3 (2.5) for antihistamines, 5.6 (3.2) for low-dose naltrexone, and 5.6 (3.1) for benzodiazepines.
Conclusion
MCAS subjects have significantly elevated odds ratios for many neuropsychiatric disorders and may see improvement of symptoms using MCAS-targeted therapies, suggesting that mast cell dysregulation affects the brain and peripheral nervous systems and contributes to neuropsychiatric symptoms. Certain mast cell mediators, specific genetic predisposition, and life experiences could determine which disorder is apt to develop or worsen.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology Department, Gastrointestinal Alliance, 11525 Olde Cabin Road, St. Louis, MO, 63141, USA.
- AIM Center for Personalized Medicine, Senior Consultant in Hematology/Oncology, Department of Mast Cell Studies, 3010 Westchester Avenue, Suite 404, Armonk, NY, 10577, USA.
- Washington University in St. Louis School of Medicine, Department of Psychiatry Box 8134, 660 S Euclid Ave, St. Louis MO, 63110, USA.
- PatientsCount.org, 13285 Roundhill Drive, Truckee, CA, 96161, USA.
- Clinical Associate Professor of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY 14203, USA.
- Neuroveda Health, 1700 Westlake Ave N, Suite 100, Seattle, WA, 98109, USA.
Zitieren
APA
Weinstock, L. B., Afrin, L. B., Reiersen, A. M., Brook, J., Blitshteyn, S., Ehrlich, G., Schofield, J. R., Kinsella, L., Kaufman, D., Dempsey, T., & Molderings, G. J. (2025). Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain, Behavior, & Immunity - Health, 48, 101048. https://doi.org/10.1016/j.bbih.2025.101048
Vancouver
Weinstock LB, Afrin LB, Reiersen AM, Brook J, Blitshteyn S, Ehrlich G, et al. Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain, Behavior, & Immunity - Health. 2025;48:101048. doi:10.1016/j.bbih.2025.101048
BibTeX
@article{Weinstock2025,
author = {Weinstock, Leonard B and Afrin, Lawrence B and Reiersen, Angela M and Brook, Jill and Blitshteyn, Svetlana and Ehrlich, Gillian and Schofield, Jill R and Kinsella, Laurence and Kaufman, David and Dempsey, Tania and Molderings, Gerhard J},
title = {Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome},
journal = {Brain, Behavior, & Immunity - Health},
year = {2025},
volume = {48},
pages = {101048},
doi = {10.1016/j.bbih.2025.101048}
}
EUVIMED